<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199328</url>
  </required_header>
  <id_info>
    <org_study_id>D961FC00011</org_study_id>
    <nct_id>NCT01199328</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Interaction Between Aspirin and Nexium</brief_title>
  <official_title>A Phase I, Open, Two-way Crossover, Drug-drug Interaction Study Evaluating the Effect of Esomeprazole on the Pharmacodynamics of Acetylsalicylic Acid After 5 Days of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the interaction between aspirin and Nexium in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of esomeprazole on low-dose aspirin pharmacodynamics by assessing the relative change in the VerifyNow Aspirin test after 5 days of treatment, relative to baseline (Day 1) in healthy human volunteers</measure>
    <time_frame>Ongoing throughout the study from consent through withdrawal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of esomeprazole on low-dose aspirin pharmacodynamics by assessing the relative change in serum thromboxane B2 inhibition from baseline</measure>
    <time_frame>Ongoing throughout the study from consent through withdrawal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety and tolerability of esomeprazole taken concurrently with low- dose aspirin</measure>
    <time_frame>Ongoing throughout the study from consent through withdrawal</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 81 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole 20mg/aspirin 81mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>81mg Tablet oral, once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>20 mg Tablet oral, once daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision informed consent prior to any study specific procedures.

          -  Healthy male and female subjects aged 18 to 75 years with suitable veins for
             cannulation or repeated vein puncture.

          -  Healthy female subjects must be of non-childbearing potential (post-menopausal, had a
             hysterectomy and/or bilateral oophorectomy) or be of childbearing potential and have a
             negative serum hCG pregnancy test during screening and be using of the following
             methods of birth control:

          -  Continuously practice abstinence during screening and throughout the duration of the
             study

          -  Clinically accepted contraception as described under item 7 of Section 5.1 and on
             hormonal contraceptives.

          -  Have a body mass index (BMI) between 19 and 30 kg/m2

          -  No clinically significant abnormal findings as judged by the Investigator on
             enrollment physical exam.

        Exclusion Criteria:

          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site)

          -  Previous enrolment or randomisation in the present study.

          -  History of any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study
             e.g. history of any bleeding disorder, excessive bruising or ongoing or history of
             liver disease

          -  History or presence of clinically significant gastrointestinal e.e. GI ulcer, hepatic
             or renal disease or any other condition known to interfere with absorption,
             distribution, metabolism or excretion of drugs.

          -  Any clinically significant illness within 4 weeks of the first administration of
             investigational product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis N Morrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bio-Kinetic Clinical Applications</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tore Lind</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynne Durborow</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <last_update_submitted>November 18, 2010</last_update_submitted>
  <last_update_submitted_qc>November 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>MDS</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Nexium</keyword>
  <keyword>aspirin</keyword>
  <keyword>peptic ulcers</keyword>
  <keyword>pharmacodynamic (PD)</keyword>
  <keyword>Esomoeprazole</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

